Brainstorm Cell Therapeutics (NASDAQ:BCLI) Given New $5.00 Price Target at Maxim Group

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) had its price objective trimmed by Maxim Group from $8.00 to $5.00 in a research note published on Tuesday morning, The Fly reports.

Separately, StockNews.com downgraded Brainstorm Cell Therapeutics from a hold rating to a sell rating in a report on Thursday, November 3rd.

Brainstorm Cell Therapeutics Price Performance

BCLI stock opened at $1.73 on Tuesday. The firm’s fifty day simple moving average is $3.56 and its 200-day simple moving average is $3.19. The company has a market capitalization of $63.12 million, a P/E ratio of -2.62 and a beta of -0.30. Brainstorm Cell Therapeutics has a 12 month low of $1.09 and a 12 month high of $4.70.

Brainstorm Cell Therapeutics (NASDAQ:BCLIGet Rating) last issued its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.04). As a group, sell-side analysts forecast that Brainstorm Cell Therapeutics will post -0.68 earnings per share for the current year.

Institutional Investors Weigh In On Brainstorm Cell Therapeutics

Several hedge funds have recently modified their holdings of BCLI. Raymond James & Associates raised its holdings in Brainstorm Cell Therapeutics by 30.6% in the 3rd quarter. Raymond James & Associates now owns 244,803 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 57,400 shares during the period. JPMorgan Chase & Co. lifted its position in shares of Brainstorm Cell Therapeutics by 27.5% during the 1st quarter. JPMorgan Chase & Co. now owns 246,202 shares of the biotechnology company’s stock valued at $827,000 after buying an additional 53,036 shares in the last quarter. TRU Independence Asset Management 2 LLC acquired a new stake in Brainstorm Cell Therapeutics in the 3rd quarter valued at $194,000. Renaissance Technologies LLC increased its holdings in Brainstorm Cell Therapeutics by 225.7% in the 3rd quarter. Renaissance Technologies LLC now owns 55,700 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 38,600 shares in the last quarter. Finally, Creative Planning acquired a new position in Brainstorm Cell Therapeutics during the third quarter worth $136,000. 10.83% of the stock is owned by hedge funds and other institutional investors.

About Brainstorm Cell Therapeutics

(Get Rating)

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.

Further Reading

The Fly logo

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.